Gainers

• Akari Therapeutics (NASDAQ:AKTX) stock increased by 40.3% to $7.21 during Thursday's after-market session. The company's market cap stands at $122.5 million. The company's, Q1 earnings came out 2 days ago.
• BioNTech (NASDAQ:BNTX) stock rose 10.59% to $100.56. The market value of their outstanding shares is at $22.8 billion.
• Polaryx Therapeutics (NASDAQ:PLYX) stock moved upwards by 10.02% to $4.33. The market value of their outstanding shares is at $160.0 million. As per the news, the Q1 earnings report came out 4 days ago.
• QTREX Quantum Ltd. - Ordinary Shares (NASDAQ:QTEX) shares rose 8.94% to $0.33.
• Outlook Therapeutics (NASDAQ:OTLK) stock moved upwards by 8.7% to $0.36. The company's market cap stands at $32.9 million. As per the press release, Q2 earnings came out 4 days ago.
• Dyadic International (NASDAQ:DYAI) stock increased by 8.1% to $0.8. The company's market cap stands at $26.8 million.

Losers

• NervGen Pharma (NASDAQ:NGEN) stock decreased by 23.9% to $2.8 during Thursday's after-market session. The company's market cap stands at $302.6 million.
• rYojbaba (NASDAQ:RYOJ) stock declined by 7.45% to $1.86. The company's market cap stands at $22.0 million.
• Adagene (NASDAQ:ADAG) stock decreased by 6.87% to $3.53. The company's market cap stands at $227.9 million.
• Liminatus Pharma (NASDAQ:LIMN) shares fell 6.75% to $0.23. The market value of their outstanding shares is at $8.4 million.
• BiomX (AMEX:PHGE) stock decreased by 6.3% to $0.69. The company's market cap stands at $6.0 million. The company's, Q1 earnings came out yesterday.
• Jupiter Neurosciences (NASDAQ:JUNS) stock decreased by 5.32% to $0.26. The company's market cap stands at $7.4 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.